$9.67
6.73% yesterday
Nasdaq, May 20, 10:09 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$9.67
+1.75 22.10% 1M
-3.45 26.30% 6M
-1.99 17.07% YTD
-16.22 62.65% 1Y
-38.07 79.74% 3Y
-10.13 51.16% 5Y
-12.43 56.24% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.61 6.73%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Market capitalization $1.00b
Enterprise Value $617.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.54
P/S ratio (TTM) P/S ratio 21.98
P/B ratio (TTM) P/B ratio 1.28
Revenue growth (TTM) Revenue growth -13.37%
Revenue (TTM) Revenue $45.57m
EBIT (operating result TTM) EBIT $-534.57m
Free Cash Flow (TTM) Free Cash Flow $-381.16m
Cash position $503.75m
EPS (TTM) EPS $-5.23
P/E forward negative
P/S forward 17.98
EV/Sales forward 11.08
Short interest 31.59%
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Intellia Therapeutics, Inc. forecast:

22x Buy
76%
6x Hold
21%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
76%
Hold
21%
Sell
3%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
46 46
13% 13%
100%
- Direct Costs 10 10
9% 9%
23%
35 35
18% 18%
77%
- Selling and Administrative Expenses 107 107
3% 3%
235%
- Research and Development Expense 453 453
3% 3%
993%
-524 -524
3% 3%
-1,151%
- Depreciation and Amortization 10 10
9% 9%
23%
EBIT (Operating Income) EBIT -535 -535
3% 3%
-1,173%
Net Profit -526 -526
8% 8%
-1,154%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 18 hours ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
3 days ago
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneurop...
Neutral
Seeking Alpha
6 days ago
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today